Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AHCO vs TNDM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AHCO Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

AHCO Overall Winner 6-Pillar Tally: AHCO 4 – 2 TNDM Matrix Metrics: AHCO 6 – 4 TNDM

As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Tandem Diabetes Care, Inc. (TNDM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas TNDM carries 43.3/100 (HOLD) at $17.46 (N/M Forward P/E, -2.4% operating margin).

  • Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile TNDM is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AHCO vs TNDM
AHCO NASDAQ Head-to-Head Winner
AdaptHealth Corp. Common Stock
Services-Home Health Care Services
$7.20
-0.69% 1D
Market Cap $989.8M
TTM Revenue $3.44B
Forward P/E 7.8x
Beta / 30D Vol 0.17β · 67% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $6.96 · SMA50: $6.32
TNDM NASDAQ
Tandem Diabetes Care, Inc.
Surgical & Medical Instruments & Apparatus
$17.46
+3.93% 1D
Market Cap $1.2B
TTM Revenue $1.08B
Forward P/E N/M
Beta / 30D Vol 1.07β · 92% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 54.0 Fund 50.0 Flow 70.0 Mom 21.1
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -6.2%) with fading momentum, RSI 48
RSI-14: 48.0 · SMA20: $18.35 · SMA50: $17.25

6-Pillar Scorecard Institutional Category Breakdown (AHCO 4 – 2 TNDM)

Columns: Metric · AHCO · TNDM
1. Valuation Multiples AHCO
Forward P/E 7.8x N/M
Trailing P/E 7.8x N/M
PEG Ratio N/M N/M
EV / Revenue 0.9x 1.7x
2. Growth & Scale TNDM
Revenue Growth (YoY) +10.9% +13.8%
Earnings Growth (YoY) +6.7% -37.0%
TTM Revenue (USD) $3.44B $1.08B
Market Cap $989.8M $1.2B
3. Profitability & Quality AHCO
Gross Margin 18.2% 56.6%
Operating Margin 3.8% -2.4%
Net Profit Margin -11.8% -4.6%
Return on Equity (ROE) -28.4% -36.7%
4. Balance Sheet & Cash Flow AHCO
Cash Generation (TTM) $82M -$71M
Cash Flow Margin 2.4% -6.6%
Net Cash / Leverage $1.97B Net Debt (1.67x D/E) $664M Net Debt (5.45x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AHCO
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 66.9% (12th %ile) 11.3% (<1st %ile)
Put/Call OI Skew N/A 0.39x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat TNDM
OpEx & R&D Intensity 14.4% of Rev ($495M) 59.0% of Rev ($635M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AHCO (6) vs TNDM (4)
Institutional Metric AHCO TNDM Criterion Row Edge
Market Capitalization
Scale
$989.8M $1.2B Larger Scale TNDM
Trailing P/E Ratio
Valuation
7.8x N/M Lower Multiple AHCO
Forward P/E Ratio
Valuation
7.8x N/M Lower Multiple AHCO
Revenue Growth (YoY)
Growth
+10.9% +13.8% Higher Growth TNDM
Operating Margin (TTM)
Profitability
3.8% -2.4% Higher Margin AHCO
Net Profit Margin
Profitability
-11.8% -4.6% Higher Margin TNDM
Return on Equity (ROE)
Capital Efficiency
-28.4% -36.7% Higher ROE AHCO
52-Week Range Position
Momentum
24% ($5–$13) 30% ($12–$30) Stronger Trend TNDM
Beta / 30D Volatility
Risk Regime
0.17β · 67% Vol 1.07β · 92% Vol Lower Realized Risk AHCO
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 43.3 / 100 (HOLD) Higher Composite AHCO
Trailing 12M Revenue (USD)
Operating Scale
$3.44B $1.08B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.2% 56.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · 1.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$82M ($1.97B Net Debt (1.67x D/E)) -$71M ($664M Net Debt (5.45x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AHCO +14.88 pp
AHCO: +16.69% · TNDM: +1.81%
3M Horizon AHCO +49.31 pp
AHCO: +27.89% · TNDM: -21.42%
6M Horizon TNDM +47.77 pp
AHCO: -31.1% · TNDM: +16.67%
1Y Horizon TNDM +14.05 pp
AHCO: -20.88% · TNDM: -6.83%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AHCO Revenue TNDM Revenue AHCO Op. Margin TNDM Op. Margin Margin Leader
FY2018 $350M $180M 9.0% -24.3% AHCO
FY2019 $530M $360M 5.5% -4.6% AHCO
FY2020 $1.06B $500M 6.8% -1.6% AHCO
FY2021 $2.45B $700M 9.2% 3.2% AHCO
FY2022 $2.97B $800M 6.4% -11.6% AHCO
FY2023 $3.20B $750M -18.7% -31.2% AHCO
FY2024 $3.26B $940M 8.1% -10.5% AHCO
FY2025 $3.24B $1.01B 2.8% -18.5% AHCO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AHCO SURGE
6d in phase · OBV NEUTRAL
Current IV 66.9%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TNDM BREAKDOWN
72d in phase · OBV DISTRIBUTION
Current IV 11.3%
IV Percentile <1st %ile
Put/Call OI Skew 0.39x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TNDM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AHCO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment 14.4% of Rev ($495M)
90D Engineering Disclosures 0 Published
TNDM Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.2B market capitalization and -2.4% operating margin.
OpEx & R&D Reinvestment 59.0% of Rev ($635M)
90D Engineering Disclosures 0 Published

Investor FAQ AHCO vs TNDM Key Questions & Quantitative Answers

As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Tandem Diabetes Care, Inc. (TNDM) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas TNDM carries 43.3/100 (HOLD) at $17.46 (N/M Forward P/E, -2.4% operating margin). Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile TNDM is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TNDM leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with TNDM at +13.8% YoY revenue growth and -37.0% YoY earnings growth on $1.08B TTM revenue (56.6% gross margin, -2.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AHCO cumulative revenue shifted +825.7% while TNDM shifted +461.1%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus 59.0% of Rev ($635M) (0 disclosures) for TNDM.

AHCO screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas TNDM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.7x EV/Revenue (-6.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus TNDM (-36.7% ROE) capital efficiency.

In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, TNDM carries 11.3% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.39x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.07β · 92% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.